After a remarkable run in the 2nd half of in 2015 and Q1 2021, hedge fund investors and managers were expecting a similar program in Q2 as well. They were right, with Q2 proving another robust quarter for the hedge fund market. As per Citco Fund Services quarterly hedge fund report, about 82% of the hedge funds were in the green in Q2, a boost of about 9% from Q1. Not all hedge funds were able to post positive returns, and some fared worst than others. Lets take an appearance at the ten worst carrying out hedge funds in Q2 2021.
Get The Full Walter Schloss Series in PDF
Get the entire 10-part series on Walter Schloss in PDF. Wait to your desktop, read it on your tablet, or e-mail to your colleagues.
Q3 2021 hedge fund letters, conferences and more
10 Worst Performing Hedge Funds In Q2 2021
We have used the quarterly return data from insidermonkey.com to rank the 10 worst performing hedge funds in Q2 2021. Following are the ten worst performing hedge funds in Q2 2021:
The top 5 holdings of this hedge fund are: Mitek Systems, Gds Holdings, Magnachip Semiconductor, Tenable Holdings, and Impinj. Its greatest sell in Q2 was BenefitFocus.
Founded in 2007, this company uses personalized financial investment and advisory solutions to financiers globally, and has Jose Fernandez as supervisor. The top five holdings of this hedge fund are: Datadog, Tenable Holdings, Duck Creek Technologies, Jfrog and Oyster Point Pharma. Its biggest sell in Q2 was Duck Creek Technologies. Stepstone Group is headquartered in La Jolla, Calif. and its portfolio worth is more than $7 million.
Ghost Tree Capital (-15.8%).
Established in 2009, it is a private & & household services company that has Jim Simons as manager. The leading 5 holdings of this hedge fund are: Pmv Pharmaceuticals, 23Andme Holding, 23Andme Holding, Denali Therapeutics and Rapt Therapeutics. Euclidean Capital is headquartered in New York, and its portfolio worth is more than $427 million.
Updated on Oct 21, 2021, 10:49 am.
Euclidean Capital (-27%).
Founded in 2019, it is an essential biotechnology-focused mutual fund that has Arsani William as supervisor. The top 5 holdings of this hedge fund are: Alx Oncology Holdings, Olema Pharmaceuticals, Design Therapeutics, Verve Therapeutics and Dyne Therapeutics. Its most significant sell in Q2 was Repare Therapeutics. Logos Capital is headquartered in San Francisco, and its portfolio value is more than $1,189 million.
Acuta Capital Partners (-21.8%).
Founded in 2016, it is a financial investment advisor that has Wnag Chan as manager. The top five holdings of this hedge fund are: Zto Express (Cayman), Bright Scholar Education Holdings, Puxin, Ke Holdings and New Orient Education and Technology Group. Its most significant sell in Q2 was New Orient Education and Technology Group. Peacefulness Capital is headquartered in Palo Alto, Calif. and its portfolio value is more than $192 million.
Peacefulness Capital (-20.8%).
Established in 2011, it is a financial investment banking company that has Manfred Yu as supervisor. It has actually invested considerably in healthcare securities. The top five holdings of this hedge fund are: Vistagen Therapeutics, Celldex Therapeutics, Celldex Therapeutics (Put), Apellis Pharmaceuticals and Arrowhead Pharmaceuticals. Its greatest sell in Q2 was 89bio. Acuta Capital Partners is headquartered in Belmont, Calif. and its portfolio worth is more than $250 million.
Biotechnology Value Fund/ BVF Inc (-14.2%).
The leading five holdings of this hedge fund are: Alx Oncology Holdings, Olema Pharmaceuticals, Design Therapeutics, Verve Therapeutics and Dyne Therapeutics.
Established in 1999, this company invests mainly in metals and mining markets, and has Peter Franklin Palmedo as manager. The leading 5 holdings of this hedge fund are: Spdr Gold Trust (Call), Spdr Gold Trust (Put), Penn Virginia Gp Holdings, Alamos Gold and Perpetua Resources. Sun Valley Gold is headquartered in Sun Valley, Idaho and its portfolio worth is more than $1,837 million.
Sun Valley Gold (-15.1%).
After an impressive run in the second half of last year and Q1 2021, hedge fund financiers and supervisors were expecting a comparable program in Q2. They were right, with Q2 showing another robust quarter for the hedge fund industry. As per Citco Fund Services quarterly hedge fund report, about 82% of the hedge funds were in the green in Q2, a boost of about 9% from Q1. Lets take an appearance at the 10 worst carrying out hedge funds in Q2 2021.
Stepstone Group (-15.4%).
Toronado Partners (-15.8%).
Founded in 1993, this fund specializes in fundamentally-driven public biotechnology financial investments and has Mark Lampert as supervisor. The top five holdings of this hedge fund are: Gh Research, Argenx Se, Olema Pharmaceuticals, Protagonist Therapeutics and Merus.
Branding Capital (-19.5%).
Founded in 2013, this hedge fund company utilizes long/short equity method and focuses on the health care industry. Ken Greenberg and David Kim are its managers. The top 5 holdings of this hedge fund are: Spdr Series Trust (CALL), Rapt Therapeutics, Ascendis Pharma, Fate Therapeutics and Xenon Pharmaceuticals. Ghost Tree Capital is headquartered in New York, and its portfolio worth is more than $343 million.
Established in 2016, this business offers financial investment advisory services, and has Srini Akkaraju and Michael Dybbs as supervisors. Samsara BioCapital mostly buys the life sciences, oncology, and digital healthcare sectors. The top 5 holdings of this hedge fund are: Graphite Bio, Nkarta, Chinook Therapeutics, Novavax (call) and Instil Bio. Samsara BioCapital is headquartered in Palo Alto, Calif. and its portfolio value is more than $800 million.
Samsara BioCapital (-23.7%).
